The September issue of EMJ is out now, and focuses on rare diseases and the challenges associated with their diagnosis and management. This issue showcases fascinating reviews, research articles, and case reports from across medical disciplines, including research into the impact of the COVID-19 pandemic on rare disease diagnostics. An interview with Yann Le Cam, Founder and Chief Executive Officer of EURORDIS-Rare Diseases Europe, highlights sustainability in Europe and the need for patient advocacy in rare disease protocols.
EMJ 7.3 2022
Latest articlesAll articles
Oral Corticosteroids for Patients with Eosinophilic Diseases: An Expert Panel View on Use, Overuse, and Strategies to Reduce Use
Severe asthma (SA), chronic rhinosinusitis with nasal polyps (CRSwNP), and eosinophilic granulomatosis with polyangiitis (EGPA) are three conditions driven by IL-5 and eosinophilic inflammation. As these conditions have high use of healthcare services, as well as lifestyle and psychological burdens, well-tolerated treatment to achieve optimal control is key.
Ocedurenone: A Novel Therapy for Uncontrolled Hypertension in Advanced Chronic Kidney Disease
Setting the scene, Bakris defined CKD as a reduction in kidney function (estimated glomerular filtration rate [eGFR] <60 mL/min/1.73 m2), alongside the presence of albuminuria (≥30 mg/day) as an indication of kidney damage.
Heated Tobacco Products and Chronic Obstructive Pulmonary Disease: A Narrative Review of Peer-Reviewed Publications
An estimated 65 million people worldwide have moderate or severe chronic obstructive pulmonary disease (COPD), an umbrella term used to describe a group of progressive lung diseases that obstruct airflow such as emphysema and chronic bronchitis. Smoking contributes to an estimated 90% of COPD cases, as the harmful chemicals produced during tobacco combustion damage the lungs and airways. Although smoking cessation is the only intervention shown to improve COPD prognosis in smokers, many patients who try to quit continue to smoke.